|
End-of-day quote
Korea S.E.
08/09/2026
|
5-day change | 1st Jan Change | ||
| 99,100.00 KRW | +1.64% |
|
-6.07% | -29.42% |
Company Valuation: OliX Pharmaceuticals, Inc
Data adjusted to current consolidation scope
| Fiscal Period: December | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| Market Cap 1 | 355,531 | 2,834,660 | 2,087,328 | - |
| Change | - | 697.3% | -26.36% | - |
| Enterprise Value (EV) | 355,531 | 2,834,660 | 2,087,328 | 2,087,328 |
| Change | - | 697.3% | -26.36% | 0% |
| P/E | -7.98x | -176x | -64x | -65.8x |
| PBR | - | - | 33x | 34.1x |
| PEG | - | 2.6x | -0.7x | 23.69x |
| Capitalization / Revenue | - | 193x | 261x | 190x |
| EV / Revenue | - | 0x | 261x | 190x |
| EV / EBITDA | - | -0x | -72x | -74.5x |
| EV / EBIT | - | -0x | -67.3x | -69.6x |
| EV / FCF | - | - | -61.4x | -63.3x |
| FCF Yield | - | - | -1.63% | -1.58% |
| Dividend per Share 2 | - | - | - | - |
| Rate of return | - | - | - | - |
| EPS 2 | -2,414 | -800 | -1,548 | -1,505 |
| Distribution rate | - | - | - | - |
| Net sales 1 | - | 14.67 | 8 | 11 |
| EBITDA 1 | - | -27.52 | -29 | -28 |
| EBIT 1 | - | -30.46 | -31 | -30 |
| Net income 1 | -19.1 | -16.23 | -31 | -30 |
| Net Debt | - | - | - | - |
| Reference price 2 | 19,260.00 | 140,400.00 | 99,100.00 | 99,100.00 |
| Nbr of stocks (in thousands) | 18,460 | 20,190 | 21,063 | - |
| Announcement Date | 21/03/25 | 12/02/26 | - | - |
1KRW in Billions2KRW
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -62.98x | - | - | - | 1.53B | |
| 19.9x | 7.03x | 14.13x | 1.49% | 67.82B | |
| 35.92x | 9.37x | 28.59x | 0.04% | 63.22B | |
| -77.3x | 14.92x | -71.95x | -.--% | 27.58B | |
| -15.84x | 6.12x | -7.7x | -.--% | 26.06B | |
| 29.27x | 6.25x | 16.23x | -.--% | 25.38B | |
| 27.11x | 5.08x | 16.9x | -.--% | 19.89B | |
| 49.98x | 18.45x | 37.42x | 0.3% | 17.4B | |
| 1291.85x | 37.31x | 814.25x | -.--% | 14.95B | |
| 18.23x | 5.44x | 12.69x | -.--% | 14.62B | |
| Average | 131.61x | 12.22x | 95.62x | 0.2% | 27.85B | |
| Weighted average by Cap. | 81.57x | 10.32x | 51.78x | 0.39% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- A226950 Stock
- Valuation OliX Pharmaceuticals, Inc
Select your edition
All financial news and data tailored to specific country editions
